Clinical trials News Recent research Fulcrum announces results from ReDUX4 Trial with Losmapimod in FSHD June 24, 2021 By Bine Haase Fulcrum-Therapeutics-Announces-Results-from-ReDUX4-Trial-with-Losmapimod-in-Facioscapulohumeral-Muscular-Dystrophy-FSHD-Demonstrating-Slowed-Disease-Progression-and-Improved-FunctionDownload Post navigation Previous PostPrevious Today is World FSHD Day!Next PostNext A “patient friendly” summary by FSHD Society on the results of Fulcrums phase 2b study on Losmapimod